ReviewCurrent atherosclerosis reports2026
Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT.
Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cardiovascular Outcomes with Colchicine in Coronary Artery Disease and HFpEF: A Propensity-Matched TriNetX Analysis.Journal of cardiovascular development and disease · 2026Article
- Interaction between high-sensitivity C-reactive protein and mean platelet volume for 1-year major adverse cardiovascular events in stable coronary artery disease.Scientific reports · 2026Article
- Multimodal Cardiac Imaging in Systemic Lupus Erythematosus: From Clinical Suspicion to Diagnosis in Clinical Practice.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review examines differences between three large colchicine trials, including study design, trial populations, timing of treatment initiation, colchicine dosing regimens, geographic factors, the timing of trial conduct and inflammatory response. RECENT
findingsColchicine inhibits neutrophil function and affects nucleotide-binding oligomerisation domain-like receptors, pyrin domain-containing 3 (NLRP3) inflammasome activity, thereby reducing the release of downstream pro-inflammatory cytokines such as mature interleukin-1β and interleukin-6. Large randomized controlled trials have evaluated the effects of colchicine in the secondary prevention of coronary artery disease with divergent results. The Colchicine Cardiovascular Outcomes Trial (COLCOT) in patients with recent myocardial infarction (MI) and the Low-Dose Colchicine 2 (LoDoCo2) trial in patients with chronic coronary syndrome showed relative risk reductions of 23% and 31% for major adverse cardiovascular events (MACE). In contrast, the CLEAR SYNERGY trial in patients with recent MI yielded neutral results. Differences between COLCOT, LoDoCo2 and CLEAR SYNERGY provide insights into these aspects of the trials, but do not give definite answers as to why results were divergent. Future detailed analyses of CLEAR SYNERGY, such as stratification by time to treatment initiation, landmark analyses, re-evaluation of events, and assessments of the relationship between inflammatory response and outcomes, could provide additional insights.
Indexed as
Identifiers
41528549What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.